Summary 57 primary tumour samples from Indian oral cancer patients with a 5-15 year tobacco chewing habit, were examined for mutational activation in codons 12, 13 and 61 of the H-ras, K- 
Squamous cell carcinoma (SCC) of the oral cavity are a major cause of mortality in several developing countries, comprising 40-50% of all malignancies in parts of India and South East Asia (Pindborg, 1977; Sanghavi, 1981; Daftary, 1990) . This high prevalence is in contrast to 2-4% of the total malignancies in the developed Western countries (Binnie, 1976; Field & Spandidos, 1987) . In India, there is an unequivocal relationship between chewing tobacco and oral cancer (Daftary, 1990; Gupta et al., 1987; Jussawalla & Deshpande, 1971) . Oral malignancies in developed Western countries are also associated with tobacco, used either in cigarettes (Wynder & Stellman, 1977) ; or as moist snuff placed between the cheek and gum (Winn, 1984) . In general, most tobacco-related oral malignancies in India are preceded by a clinically distinctive premalignant stage such as leukoplakia (Daftary, 1990) . Oral SCCs in developed countries may be, but usually are not, preceded by the appearance of premalignant lesions (Binnie, 1990) .
Recently, several oncogenes previously shown to be involved in various human malignancies (Klein & Klein, 1985; Yokota et al., 1986) , have been implicated in oral cancers (Field & Spandidos, 1987; Hoellering & Shuler, 1988; Saranath et al., 1989; Saranath et al., 1990) . In the Indian cases of oral SCCs examined by Saranath and co-workers (1989), a 5-to 10-fold amplification of one or more of the c-myc, N-myc, K-ras and N-ras oncogenes was observed in 13/23 (56%) of the tumour samples. Multiple oncogene amplification was correlated with advanced disease stages III and IV. Neither L-myc nor H-ras were amplified in the SCCs. Further, studies on restriction fragment length polymorphism (RFLP) with respect to L-myc in oral cancer patients demonstrated the S allele (6.6kb EcoRI fragment) predominating in poor to moderately differentiated tumours, as well as larger sized tumours (Saranath et al., 1990) .
Mutations leading to the activation of cellular ras protooncogenes have been identified in several human malignancies of diverse origin (Bos, 1989) . The family of ras genes includes three well characterised genes, H-ras, K-ras and N-ras, encoding 21 kDa proteins that bind guanine nucleotides, possess GTPase activity and are localised at the inner surface of the plasma membrane (Barbacid, 1987) . In vivo mutations in ras genes have been restricted to codons 12, 13 and 61, although in vitro mutations in several other codons have transforming activities (Bos, 1989) . Saiki et al. (1985) were the first to describe the use of synthetic oligonucleotide probes to detect and identify point mutations in DNA enzymatically amplified in vitro by the polymerase chain reaction (PCR) technique. PCR has been used in several studies identifying ras mutations in human malignancies. In this study we (Saiki et al., 1985) , and conditions recommended by Perkin Elmer Cetus for their Thermocycler. Each PCR reaction in a total volume of 100 gl, contained 1l g genomic DNA, 10 mM Tris (pH 7.5), 50 mM NaCl, 10 mM MgCl2, 1.5 mM of each dNTP and 1 1tmol of each primer (two of each reaction). The tubes were held at 94°C for 5 min and then cooled to 55°C before addition of 1 unit of Taq polymerase (Cetus). For H-ras the pairs of primers used in the PCR reactions are described in Figure 1, Hybridisation of the filters with the oligonucleotide probes was carried out overnight. The oligoprobes (20 mers) were 5'-end labelled by phosphorylation with 20 gLCi ('y32P) ATP (Amersham, specific activity 5,000 mCi mmol-') and T4 polynucleotide kinase (Bethesda Research Laboratory). Washing of the filters, except those for H-ras codon 61, was carried out in 3 M tetramethylammonium chloride (Fluka) containing 50 mM Tris (pH 8.6), 2 mM EDTA and 0.1% SDS at 63°C for 20 min. The H-ras codon 61 filters were washed at 67°C for 20 min in 5 x SSC containing 0.1% SDS. The filters were exposed to Fuji X-ray films at -70°C using intensifying screens, for a period of 1-15 h.
Initial screening of the amplified DNA utilised mixed probes, each set covering one nucleotide position of a particular codon. On indication of a mutation, a duplicate PCR of the genomic DNA was performed, and the two independently amplified DNAs were then screened simultaneously with a set of single oligonucleotide probes specific for the nucleotide position. The presence of wild-type codons were screened for, in every set of blots. Table I (Figure 2 ). b point mutations in codons 12, 13 or 61 of the H-ras gene. Further, the mutations were restricted to H-ras, with none of the 57 samples showing mutations in codons 12, 13 and 61 of the K-ras and N-ras oncogenes. The point mutations were predominantly in H-ras codon 61.2 (10/20), corresponding to a glutamine to arginine substitution, and codon 12.2 (7/20) corresponding to a glycine to valine substitution. Two of the samples (17BM and 33LA) were unique in carrying both the commonly occurring H-ras 61.2 and 12.2 mutations described. It is not known whether the pair of mutations in these two samples exist on a common H-ras allele or arose from two distinct clonal populations.
In eight of the 20 cases with point mutations, an apparent absence of the wild-type H-ras allele was observed, indicating a deletion or loss of the normal H-ras allele, with or without duplication of the mutated H-ras gene. In patient 28BM, RFLP studies indicated loss of one H-ras allele (Table II; Saranath et al., data unpublished). However, in patient 17BM, where both a H-ras 12.2 and 61.2 mutation were observed, there was no signal for a wild-type H-ras codon 12 on the dot blots (Figure 2) , whilst there was a positive signal for a wild-type H-ras 61 codon (Figure 2) . In this patient, the 12.2 mutation may exist in both alleles, whilst the 61.2 mutation was observed in only one allele. Loss of normal H-ras allele with the presence of a mutated H-ras gene has been reported in the EJ bladder carcinoma cell line (Taparowsky et al., 1982) .
Mutational activation of ras genes has been detected in a wide variety of human neoplasms including solid epithelial tissue and haematological malignancies (Bos, 1989; Bos et al., 1987) . Ras mutations have been shown to occur at a frequency between 5 and 15% (Varmus, 1984; Pierce et al., 1986) . However, a higher frequency of 25 to 50% has also been reported (Bos et al., 1985; Needleman et al., 1986; Farr et al., 1988; Forrestor et al., 1987; Lemoine et al., 1989) . In several human cancers with ras mutations, a bias for mutations to occur in a particular member of the ras family is noted. For example, H-ras mutations predominate in human bladder carcinoma (Fujita et al., 1985) , whilst K-ras mutations frequently occur in lung and colon carcinomas (Bos et al., 1987; Forrestor et al., 1987) and N-ras mutations are particularly associated with haematological malignancies (Bos et al., 1985; Needleman et al., 1986; Janssen et al., 1987) . However, the association between the malignancy and the particular member of the ras family is generally not exclusive, with few exceptions, such as pancreatic cancer and K-ras reviewed by Bos (1989) . Thus, the detection of only H-ras mutations in chewing-tobacco-related oral SCCs appears to be unique, and the high prevalence -35% amongst the 57 cases examined, is exceptional.
Previous work by some of us (Saranath et al., 1989) has shown that over 50% of chewing-tobacco-related oral SCCs in India have a 5-to 10-fold DNA amplification of one or more of the c-myc, N-myc, K-ras and N-ras oncogenes, but no amplification of H-ras or L-myc. The question of myc and ras amplifications in the 57 cases presented in this study has also been investigated (unpublished data) . A summary of this DNA amplification data is presented in Table II , indicating ras activation in Indian oral SCCs by both amplification as observed in K-ras and N-ras, and point mutations observed in H-ras.
The absence of either a normal H-ras codon 12 or 61 signal in 8/20 (40%) of the H-ras mutation positive samples on the dot blots is noteworthy. The inactivation or loss of normal H-ras alleles may be important in tumour progression, as demonstrated in colorectal (Baker et at., 1989) and breast carcinoma (Theillet et at., l1986). The apparent loss of the wild-type H-ras allele on chromosome 11, may be significant, not only for the loss of the H-ras gene itself, but for the loss or effective neutralisation of a nearby regulatory or tumour suppressor gene (Saxon et al., 1986 (Saranath et al., 1989) . Possibly H-ras mutations are important at an earlier stage of oral SCC development, with the myc and ras amplifications associated with the advanced stages (Saranath et al., 1989) . However, 12 of the 20 samples with activated ras contain a normal H-ras gene, and eight of these are T4. Thus, loss of the normal H-ras allele in these tumours containing one mutated H-ras allele is not necessary for progression to the T4 stage.
The oral cancer patients in this study were habitual tobacco chewers (5 to 15 years) and developed carcinomas at the site where the tobacco folded in 'quid' was kept for prolonged periods. Nitroso-containing compounds also present in tobacco, are known to induce H-ras mutations in experimental animals (Zarbl et al., 1985; Quintanilla et al., 1986) . Our data strongly suggest that particular carcinogen(s), probably of nitroso origin, in tobacco, can affect specific base mutations at codons 12, 13 and 61 of H-ras, leading to oral malignancies. Different carcinogens present in tobacco, may be responsible for the two major types of mutations at H-ras 12.2 and 61.2, observed in our primary oral tumours. An equal number of transitions and transversions were found amongst our H-ras mutations. In general nitrosamines preferentially (but not exclusively) produce transitions whilst other carcinogens, like benzo(a)pyrene, cause transversions.
Preliminary studies of oral SCC from patients resident in the United Kingdom shows that H-ras mutations infrequently occur among such cancers (Chang et al., unpublished) . Mutations in codons 12, 13 and 61 of H-ras, K-ras and N-ras in these UK samples is a rare event. A possible reason, for the difference in ras mutations frequency between UK and Indian tobacco-associated oral malignancies may be due to the mode of tobacco usage, the strains/species of tobacco used and the curing process in the two countries.
In summary, our data demonstrate that a major step by which chewing tobacco may cause oral malignancies is via carcinogen effected point mutations at codons 12, 13 and 61 of H-ras. This activation may occur at a relatively early stage in oral carcinogenesis. Further, inactivation or loss of the normal H-ras allele, may provide a selective advantage to the transformed clones. Since H-ras mutations may be biologically important at an early stage of oral carcinogenesis, such studies in premalignant lesions like leukoplakia are currently in progress in our laboratories. A correlation between the presence of H-ras mutations in premalignant lesions and malignant transformation, would further indicate the critical role of H-ras activation in oral carcinogenesis, and perhaps predisposition of these lesions towards oral malignancy.
